Business Context and Reporting Period
Company: Supernus Pharmaceuticals, Inc. (SUPN)
Filing Type: Form 8-K (Current Report)
Date of Report: November 8, 2022
Reporting Period: Third quarter ended September 30, 2022
This filing serves to announce the issuance of a press release regarding the Company's financial results for the third quarter of 2022. The information is furnished under Item 2.02 and is not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Key Financial Metrics
The provided text is a cover document for an 8-K filing and does not contain specific numerical data regarding revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the press release furnished as Exhibit 99.1, which is incorporated by reference but not included in the source text.
Note: The filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data versus the prior period are detailed in this specific document. The filing directs investors to the press release (Exhibit 99.1) for the full presentation of business and financial results.
Guidance, Outlook, and Risks
- Conference Call: The Company hosted a conference call on November 8, 2022, at 4:30 p.m. Eastern Time to present results. A webcast was archived on the Company's website for 60 days.
- Forward-Looking Statements: The filing contains forward-looking statements regarding plans, strategies, and intentions. These are subject to risks and uncertainties, including those detailed in Item 1A ("Risk Factors") of the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2021.
- Disclaimer: The Company undertakes no obligation to update or revise forward-looking statements.
Investor Verification Checklist
- Review the press release (Exhibit 99.1) for specific Q3 2022 revenue, net loss, and cash position figures.
- Verify the archived webcast on the Company's website for management commentary on the results.
- Consult the Form 10-K filed on April 13, 2022, for a comprehensive list of risk factors affecting forward-looking statements.
- Confirm the status of the Company's emerging growth company designation (indicated as not applicable in this filing).